United States was Immunocore Holdings’s largest region in fiscal 2025, bringing in $257.00M of $400.02M (64%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $169.79M | $226.69M | $257.00M |
| Europe | $67.63M | $73.22M | $131.42M |
| International | $1.32M | $10.08M | $11.60M |
| Total | $238.74M | $309.99M | $400.02M |
Immunocore Holdings brought in $400.02M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 29.0% from $309.99M in fiscal 2024. United States was the largest at $257.00M (64.2%), ahead of Europe at $131.42M (32.9%) and International at $11.60M (2.9%).
Compared with fiscal 2024, Europe grew fastest, up 79.5% to $131.42M. Every region above 2% of revenue grew. From fiscal 2023 to 2025, combined revenue from these regions grew from $238.74M to $400.02M, a compound annual growth rate of 29.4%. United States' share of the total fell from 71.1% to 64.2%.
Genentech was Immunocore Holdings’s largest revenue line in fiscal 2021, bringing in $24.02M of $32.41M (74%).
| Counterparty Name | FY 2021 |
|---|---|
| Genentech | $24.02M |
| Gsk | $8.39M |
| Total | $32.41M |
Immunocore Holdings brought in $32.41M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Genentech was the largest at $24.02M (74.1%), ahead of Gsk at $8.39M (25.9%).
Immunocore Holdings (IMCR) reports its revenue by geography and by counterparty name. In fiscal 2025, United States was its largest region, bringing in $257.00M (64.2% of the total), followed by Europe at $131.42M (32.9%).
United States was Immunocore Holdings' largest region in fiscal 2025, bringing in $257.00M, or 64.2% of the $400.02M total across its three regions.
Genentech was Immunocore Holdings' largest revenue line in fiscal 2021, bringing in $24.02M, or 74.1% of the $32.41M total across its two revenue lines.
Among Immunocore Holdings' regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 79.5% from $73.22M to $131.42M.
Every figure comes from Immunocore Holdings' annual financial filings, as reported. Each line keeps the name Immunocore Holdings gives it, and years follow its fiscal calendar.
Immunocore Holdings' revenue by geography goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.